Amina Ammar: Evaluating Rivaroxaban Dosing Alignment Across Cockcroft–Gault and eGFR Equations
Amina Ammar, Clinical Pharmacist at Henry Ford Wyandotte Hospital, shared a post on LinkedIn about a recent article she and her colleagues co-authered, published in Journal of Thrombosis and Thrombolysis, adding:
“Excited to share our latest publication in the Journal of Thrombosis and Thrombolysis!
Our study used data from the Michigan Anticoagulation Quality Improvement Initiative (MAQI²) Registry to evaluate differences in rivaroxaban dosing based on the method used to estimate renal function.
Grateful to everyone who contributed to this work! ”
Title: Disagreement in rivaroxaban dosing between Cockcroft–Gault and eGFR equations in nonvalvular atrial fibrillation
Authors: Amina Ammar, Stephanie Edwin, Geoffrey D. Barnes, Scott Kaatz, Deborah DeCamillo, Xiaowen Kong, Brian Haymart, Noelle Ryan, Christopher Giuliano
Stay updated with Hemostasis Today.
-
Sep 18, 2026, 16:19CRISPR and Hemophilia: The Next Frontier of In Vivo Gene Editing
-
Sep 18, 2026, 16:13Christian Irsara: PF4 Immunothrombosis Following Natural Adenovirus Infection
-
Sep 18, 2026, 16:10Leo Nicolai։ The Spleen Emerges as a Key Regulator of Thromboinflammation
-
Sep 18, 2026, 16:05Targeting Factor XI to Reduce Thrombosis Without Compromising Hemostasis – ISTH
-
Sep 18, 2026, 15:54Swapnil Pawar: Why Aren’t We Using Cryopreserved Platelets Everywhere Yet?
-
Sep 18, 2026, 15:37Abdul Mannan: Evaluating Longitudinal Platelet Trends Beyond Standard Reference Intervals
-
Sep 18, 2026, 15:30Peter A. Everts։ Platelet Phenotype May Hold the Key to More Consistent PRP Therapy
-
Sep 18, 2026, 15:25Brandon Temple: Turning Personal Experience Into Advocacy for wAIHA Research
-
Sep 18, 2026, 15:01A. M. Thirugnanam: Antiplatelet Discontinuation and the Risk of Stent Thrombosis